| 1. |
Breakthrough for angiogenesis inhibitors |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Treatment of elderly patients with acute coronary syndromes |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Legislation reinstating the US FDA's authority to require paediatric trials from drug sponsors |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Etoricoxib warranted vs traditional NSAIDs in OA, RA |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 5-6
&NA;,
Preview
|
|
摘要:
Osteoarthritis (OA) and rheumatoid arthritis (RA) are chronic conditions that lead to long-term disability and decrease the QOL of affected patients. The most widely used treatments for these conditions have mostly been traditional NSAIDs. However, these agents are commonly associated with an increased risk of GI adverse events, the prevention and/or treatment of which contributes to substantial additional costs among patients. Etoricoxib, a COX-2 inhibitor, has been shown in clinical trials to be at least as efficacious as high-dose traditional NSAIDs in managing the signs and symptoms of OA and RA. Moreover, etoricoxib is well tolerated and its use is associated with fewer clinically significant GI adverse events than traditional NSAIDs. The economic consequences of fewer GI adverse events may well be significant in the treatment of patients with OA and RA, and studies examining the related costs and efficacy issues were presented at the Annual European Congress of Rheumatology [Lisbon, Portugal; June 2003].
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Continuous SC terbutaline reduces neonatal costs in preterm labour |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Systemic corticosteroids valuable among inner-city asthma patients |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Stem cells rescue damaged pancreas |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Natalizumab*appears to be active against inflammation in patients with Crohn's disease, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
mRNA stabilisation improves oncolytic virus specificity |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Acarbose prevents CVD, hypertension in impaired glucose tolerance |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1398,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
